How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

176 results for

Dexfenfluramine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Dexfenfluramine

Dexfenfluramine Dexfenfluramine Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Dexfenfluramine Dexfenfluramine Aka: Dexfenfluramine (...) Regurgitation Occurred in women with over 1 year of Phen-Fen use References Images: Related links to external sites (from Bing) These images are a random sampling from a Bing search on the term "Dexfenfluramine." Click on the image (or right click) to open the source website in a new browser window. Related Studies (from Trip Database) Ontology: Dexfenfluramine (C0011786) Definition (MSH) The S-isomer of FENFLURAMINE. It is a serotonin agonist and is used as an anorectic. Unlike fenfluramine, it does

2018 FP Notebook

2. Investigating interactions between phentermine, dexfenfluramine, and 5-HT2C agonists, on food intake in the rat (PubMed)

Investigating interactions between phentermine, dexfenfluramine, and 5-HT2C agonists, on food intake in the rat Synergistic or supra-additive interactions between the anorectics (dex)fenfluramine and phentermine have been reported previously in the rat and in the clinic. Studies with 5-HT2C antagonists and 5-HT2C knockouts have demonstrated dexfenfluramine hypophagia in the rodent to be mediated by actions at the 5-HT2C receptor. Given the recent FDA approval of the selective 5-HT2C agonist (...) lorcaserin (BELVIQ®) for weight management, we investigated the interaction between phentermine and 5-HT2C agonists on food intake.This study aims to confirm dexfenfluramine-phentermine (dex-phen) synergy in a rat food intake assay, to extend these findings to other 5-HT2C agonists, and to determine whether pharmacokinetic interactions could explain synergistic findings with particular drug combinations.Isobolographic analyses were performed in which phentermine was paired with either dexfenfluramine

Full Text available with Trip Pro

2014 Psychopharmacology

3. Dexfenfluramine and the oestrogen metabolizing enzyme CYP1B1 in the development of pulmonary arterial hypertension. (PubMed)

Dexfenfluramine and the oestrogen metabolizing enzyme CYP1B1 in the development of pulmonary arterial hypertension. Pulmonary arterial hypertension (PAH) occurs more frequently in women than men. Oestrogen and the oestrogen-metabolising enzyme cytochrome P450 1B1 (CYP1B1) play a role in the development of PAH. Anorectic drugs such as dexfenfluramine (Dfen) have been associated with the development of PAH. Dfen mediates PAH via a serotonergic mechanism and we have shown serotonin to up-regulate

Full Text available with Trip Pro

2013 Cardiovascular Research

4. Assessment of serotonin release capacity in the human brain using dexfenfluramine challenge and [18F]altanserin positron emission tomography. (PubMed)

Assessment of serotonin release capacity in the human brain using dexfenfluramine challenge and [18F]altanserin positron emission tomography. Although alterations of serotonin (5-HT) system functioning have been proposed for a variety of psychiatric disorders, a direct method quantitatively assessing 5-HT release capacity in the living human brain is still lacking. Therefore, we evaluated a novel method to assess 5-HT release capacity in vivo using dexfenfluramine challenge and [(18)F (...) ]altanserin positron emission tomography (PET). Thirteen healthy male subjects received placebo and single oral doses of 40 mg (n = 6) or 60 mg (n = 7) of the potent 5-HT releaser dexfenfluramine separated by an interval of 14 days. Three further subjects received placebo on both days. Two hours after placebo/drug administration, 250 MBq of the 5-HT(2A) receptor selective PET-radiotracer [(18)F]altanserin was administered intravenously as a 30s bolus. Dynamic PET data were subsequently acquired over 90

2012 NeuroImage

5. Dexfenfluramine

Dexfenfluramine Dexfenfluramine Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Dexfenfluramine Dexfenfluramine Aka: Dexfenfluramine (...) Regurgitation Occurred in women with over 1 year of Phen-Fen use References Images: Related links to external sites (from Bing) These images are a random sampling from a Bing search on the term "Dexfenfluramine." Click on the image (or right click) to open the source website in a new browser window. Related Studies (from Trip Database) Ontology: Dexfenfluramine (C0011786) Definition (MSH) The S-isomer of FENFLURAMINE. It is a serotonin agonist and is used as an anorectic. Unlike fenfluramine, it does

2015 FP Notebook

6. Investigation of Serotonin Neurotransmission in MDMA Users Using Combinated Dexfenfluramine Challenge and PET Imaging

Investigation of Serotonin Neurotransmission in MDMA Users Using Combinated Dexfenfluramine Challenge and PET Imaging Investigation of Serotonin Neurotransmission in MDMA Users Using Combinated Dexfenfluramine Challenge and PET Imaging - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number (...) of saved studies (100). Please remove one or more studies before adding more. Investigation of Serotonin Neurotransmission in MDMA Users Using Combinated Dexfenfluramine Challenge and PET Imaging (DEXFEN_PET) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01296802 Recruitment Status : Completed First

2011 Clinical Trials

7. Acute Manic Relapse with Dexfenfluramine (PubMed)

Acute Manic Relapse with Dexfenfluramine 23431324 2013 02 25 2018 11 13 1738-1088 9 1 2011 Apr Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology Clin Psychopharmacol Neurosci Acute manic relapse with dexfenfluramine. 44 10.9758/cpn.2011.9.1.44 Mahendran Rathi R Institute of Mental Health/Woodbridge Hospital, Singapore. eng Journal Article 2011 04 30 Korea (South) Clin Psychopharmacol Neurosci 101207332 1738-1088 2011

Full Text available with Trip Pro

2011 Clinical Psychopharmacology and Neuroscience

8. Deconstructing Antiobesity Compound Action: Requirement of Serotonin 5-HT(2B) Receptors for Dexfenfluramine Anorectic Effects. (PubMed)

Deconstructing Antiobesity Compound Action: Requirement of Serotonin 5-HT(2B) Receptors for Dexfenfluramine Anorectic Effects. The now-banned anorectic molecule, dexfenfluramine, promotes serotonin release through a serotonin transporter-dependent mechanism, and it has been widely prescribed for the treatment of obesity. Previous studies have identified that 5-HT(2B) receptors have important roles in dexfenfluramine side effects, that is, pulmonary hypertension, plasma serotonin level (...) regulation, and valvulopathy. We thus investigated a putative contribution of 5-HT(2B) receptors in dexfenfluramine-dependent feeding behavior in mice. Interestingly, the hypophagic response to dexfenfluramine (3-10 mg/kg) observed in wild-type mice (1-4 h) was eliminated in mice lacking 5-HT(2B) receptors (5-HT(2B)(-/-)). These findings were further validated by the lack of hypophagic response to dexfenfluramine in wild-type mice treated with RS127445, a highly selective and potent antagonist (pKi=8.22

Full Text available with Trip Pro

2010 Neuropsychopharmacology

9. Prevention & Treatment of Hypertension - Health Behaviour Management

, Blaufox MD, Davis BR, Blaszkowski T, et al. Pharmacologic and nutritional treatment of mild hyper- tension: changes in cardiovascular risk status. Ann Intern Med 1990;112:89-95. Kolanowski J, Younnis LT, Vanbutsele R, Detry JM. Effect of dexfenfluramine treatment on body weight, blood pressure and noradrenergic activity in obese hypertensive patients. Eur J Clin Pharmacol 1992;42:599-605. Fagerberg B, Berglund A, Andersson OK, Berglund G. Weight reduction versus antihypertensive drug therapy in obese

2018 Hypertension Canada

10. Drugs That May Cause or Exacerbate Heart Failure

suppressants x Major A Valvular damage Intermediate Fenfluramine, dexfenfluramine, and sibutramine have been removed from the US market Bipolar medications Lithium x Major C Direct myofibrillar degeneration, adrenergic stimulation, calcium ion influx interference Intermediate to delayed Reversible on discontinuation Ophthalmological medications Topical β-blockers x Major C Negative inotrope Immediate to intermediate Consider lowering the dose or discontinuing; reversible on discontinuation Topical

Full Text available with Trip Pro

2016 American Heart Association

15. An Early Phase Study of Abraxane Combined With Phenelzine Sulfate in Patients With Metastatic or Advanced Breast Cancer

phenelzine sulfate administration, the active study treatment phase and the washout period at the end of study. Serotoninergic drugs may include but are not limited to the following: dexfenfluramine, fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram and venlafaxine; Previous use of nanoparticle albumin-bound paclitaxel; Known allergy to phenelzine sulfate or similar MOAI; and Known or suspected history of alcohol abuse; Contacts and Locations Go to Information from the National Library

2018 Clinical Trials

16. Carcinoid Heart Disease in Patients With Bronchopulmonary Carcinoid. (PubMed)

with resulting regurgitation and/or stenosis.Bronchopulmonary carcinoid was present in 185 patients (age 67 ± 13 years, 63% female). Carcinoid syndrome was present in 7.7% and liver metastases in 10%. Echocardiographic features of CaHD were present in just 2 (1%) patients. A 62-year-old woman underwent resection of stage 1A bronchopulmonary carcinoid without carcinoid syndrome and also received 7 months dexfenfluramine therapy. During 15-year follow-up, mitral regurgitation decreased and tricuspid

2018 Journal of Thoracic Oncology

17. Fatal postoperative systemic pulmonary hypertension in benfluorex-induced valvular heart disease surgery: A case report. (PubMed)

is the common active and toxic metabolite of all fenfluramine derivatives, the valvular and pulmonary arterial toxicity of benfluorex was much less known than that of fenfluramine and dexfenfluramine. The vast majority of benfluorex-induced valvular heart disease remains misdiagnosed as hypothetical rheumatic fever due to similarities between both etiologies. Better recognition of DI-VHD is likely to improve patient outcome.

Full Text available with Trip Pro

2017 Medicine

18. Cardiovascular safety of low-dose fenfluramine in Dravet syndrome: a review of its benefit-risk profile in a new patient population. (PubMed)

for up to 28 years.Nine controlled studies of fenfluramine and related compounds (dexfenfluramine and/or phentermine) which assessed incidence and severity of cardiac valve disease in 3,268 treated patients and 2,017 control subjects have been reported. Mild or greater aortic valve regurgitation was found in 9.6% of treated patients compared with 3.9% of control subjects, and moderate or greater mitral valve regurgitation was found in 3.1% of treated patients and 2.5% of control subjects. Nineteen DS

2017 Current medical research and opinion

19. J K Aronson – The Hitchhiker’s Guide to Clinical Pharmacology Part 2

Dexfenfluramine 1997 Cardiac valve abnormalities Withdrawn Mibefradil 1998 Too many drug interactions Withdrawn Tolcapone 1998 Hepatobiliary disorders Withdrawn Astemizole 1998 Interactions (e.g. with grapefruit juice) Withdrawn from OTC sale Sertindole 1998 Cardiac arrhythmias Withdrawn Trovafloxacin 1999 Hepatotoxicity Withdrawn Cisapride monohydrate 2000 Cardiotoxicity Withdrawn Cerivastatin 2001 Rhabdomyolysis; renal failure Withdrawn Nimesulide 2002 Hepatotoxicity Withdrawn Rofecoxib 2004 Cardiotoxicity

2016 CEBM blog

20. The role of 5‐HT2B receptors in mitral valvulopathy: bone marrow mobilization of endothelial progenitors (PubMed)

The role of 5‐HT2B receptors in mitral valvulopathy: bone marrow mobilization of endothelial progenitors Valvular heart disease (VHD) is highly prevalent in industrialized countries. Chronic use of anorexigens, amphetamine or ergot derivatives targeting the 5-HT system is associated with VHD. Here, we investigated the contribution of 5-HT receptors in a model of valve degeneration induced by nordexfenfluramine, the main metabolite of the anorexigens, dexfenfluramine

Full Text available with Trip Pro

2017 British journal of pharmacology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>